Physician profile
Daniel O Lee
NPI 1790874626
$93,439.74
in general payments reported to CMS, 2019-2025
56 companies · $9,414 in 2025
The $9,414 reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,727 · 2020: $16K · 2021: $11K · 2022: $17K · 2023: $18K · 2024: $16K · 2025: $9,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $23K · Travel and Lodging: $8,368 · Food and Beverage: $8,254 · Consulting Fee: $4,375 · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $22,750.00 |
| Travel and Lodging | $8,367.72 |
| Food and Beverage | $8,254.34 |
| Consulting Fee | $4,375.00 |
| Education | $255.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $45,088.09 | 2021-2024 | Firdapse |
| Eisai INC. | $25,742.61 | 2019-2025 | |
| Argenx US, INC. | $6,295.53 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Lundbeck LLC | $2,248.25 | 2019-2025 | Vyepti, Rexulti |
| Abbott Laboratories | $1,629.05 | 2024-2025 | Infinity |
| Ucb, INC. | $1,488.11 | 2019-2025 | Rystiggo, Briviact |
| Arbor Pharmaceuticals, INC. | $1,460.49 | 2019-2022 | |
| Abbvie INC. | $1,410.09 | 2019-2025 | |
| Harmony Biosciences LLC | $856.20 | 2020-2025 | |
| Pfizer INC. | $590.07 | 2023-2025 | |
| Biogen, INC. | $429.46 | 2019-2025 | Leqembi |
| Csl Behring | $379.10 | 2019-2025 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $361.45 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Amgen INC. | $333.67 | 2019-2025 | Uplizna, Aimovig |
| Jazz Pharmaceuticals INC. | $318.79 | 2019-2025 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.